Last reviewed · How we verify
ABVD and Radiotherapy
Brentuximab vedotin targets CD30
Brentuximab vedotin targets CD30 Used for Hodgkin lymphoma, Systemic anaplastic large cell lymphoma.
At a glance
| Generic name | ABVD and Radiotherapy |
|---|---|
| Sponsor | Fondazione Italiana Linfomi - ETS |
| Drug class | CD30-targeting antibody-drug conjugate |
| Target | CD30 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Brentuximab vedotin is an antibody-drug conjugate that binds to CD30, a protein expressed on the surface of certain cancer cells, and delivers a cytotoxic agent to these cells.
Approved indications
- Hodgkin lymphoma
- Systemic anaplastic large cell lymphoma
Common side effects
- Peripheral neuropathy
- Fatigue
- Nausea
Key clinical trials
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) (PHASE2)
- Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma (PHASE3)
- Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation. (PHASE4)
- Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma (PHASE2)
- Prognostic Significance of ctDNA in HL
- Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABVD and Radiotherapy CI brief — competitive landscape report
- ABVD and Radiotherapy updates RSS · CI watch RSS
- Fondazione Italiana Linfomi - ETS portfolio CI